FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
1.5 mg starting dose available in early January for $149 per month with savings offers; Wegovy ® pill is being produced in the US and robust supply is on-hand Wegovy ® brand is the only GLP-1 indicated for weight loss proven to help prevent life-threatening CV events for adults with established CVD and either overweight or obesity along with diet and exercise; Wegovy ® has been prescribed for approximately 3.2 million people in the US PLAINSBORO, N.J. Dec. 22, 2025 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy ® pill, the first oral GLP-1 medicine for obesity in the US. Wegovy ® pill is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. Wegovy ® pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack,
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy pill for weight loss, the first daily oral medication of its kind [CBS News]CBS News
- FDA approves Wegovy weight loss pill from Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy weight-loss pill from Novo Nordisk [USA TODAY]USA TODAY
- US regulators approve Wegovy pill for weight loss [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website